Disc Medicine, Inc. (NASDAQ:IRON) Accelerates Toward Near-Term Breakout After FDA Expedited Review
Momentum recently strengthened around the stock while balance-sheet depth and a pipeline catalyst support a bullish valuation case. Near-term momentum trades against a stretched technical profile that merits close attention.








